Deep phenotyping predicts Huntington's genotype
Crossref DOI link: https://doi.org/10.1038/nbt.3648
Published Online: 2016-08-09
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ruderfer, Douglas M
Dudley, Joel T
Text and Data Mining valid from 2016-08-01
Article History
First Online: 9 August 2016
Competing interests
: J.T.D. owns equity options in NuMedii, Inc., Ayasdi, Inc., Solve Bio, Inc., and LAM Therapeutics.